Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Content provided by Oncology On The Go. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology On The Go or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
S1 Ep159: Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors
MP3•Episode home
Manage episode 479611884 series 3304830
Content provided by Oncology On The Go. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology On The Go or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In an interview with CancerNetwork®, William Kennedy, MD, a neuro-radiation oncologist at the Ivy Brain Tumor Center, provided expert insights into the current state of radiosurgery for central nervous system (CNS) tumors. Highlighting a diverse array of available radiosurgery platforms, he explained that institutions like the Ivy Brain Tumor Center frequently use noninvasive surgical techniques with complex monitoring systems.
Kennedy further underscored the critical importance of having a nuanced understanding of each technology's capabilities and limitations, as well as those of the practicing oncologist. Emphasizing a high patient volume and a wide variety of cases at his own practice, he suggested that the expertise of the staff at the Ivy Brain Tumor Center positions them at the forefront of radiosurgery development.
According to Kennedy, novel therapeutic strategies under development at Ivy Brain Tumor Center include the investigational agent AZD1390, which is being assessed in combination with radiotherapy after surgery for patients with newly diagnosed or recurrent glioblastoma.
Despite the benefits that technology provide for research advancement and treatment, Kennedy posited that the multidisciplinary team is essential in ensuring the successful delivery of novel radiosurgery techniques. This integrated approach ensures that each patient benefits from an individualized plan that leverages the full potential of modern radiosurgery.
“[D]espite all the great technologies that we have here at Ivy, what I think makes this place great, what makes me proud to work here, and what means the most for our patients is how closely we providers communicate with each other and how closely knit of a team we are,” Kennedy stated. “Being available, showing up to the tumor board, always picking up the phone when your colleague calls to discuss a tough case, and never being afraid to ask for help—all those things I have learned since I have been in practice here. Those are what make the difference, more than anything.”
Kennedy further underscored the critical importance of having a nuanced understanding of each technology's capabilities and limitations, as well as those of the practicing oncologist. Emphasizing a high patient volume and a wide variety of cases at his own practice, he suggested that the expertise of the staff at the Ivy Brain Tumor Center positions them at the forefront of radiosurgery development.
According to Kennedy, novel therapeutic strategies under development at Ivy Brain Tumor Center include the investigational agent AZD1390, which is being assessed in combination with radiotherapy after surgery for patients with newly diagnosed or recurrent glioblastoma.
Despite the benefits that technology provide for research advancement and treatment, Kennedy posited that the multidisciplinary team is essential in ensuring the successful delivery of novel radiosurgery techniques. This integrated approach ensures that each patient benefits from an individualized plan that leverages the full potential of modern radiosurgery.
“[D]espite all the great technologies that we have here at Ivy, what I think makes this place great, what makes me proud to work here, and what means the most for our patients is how closely we providers communicate with each other and how closely knit of a team we are,” Kennedy stated. “Being available, showing up to the tumor board, always picking up the phone when your colleague calls to discuss a tough case, and never being afraid to ask for help—all those things I have learned since I have been in practice here. Those are what make the difference, more than anything.”
185 episodes
MP3•Episode home
Manage episode 479611884 series 3304830
Content provided by Oncology On The Go. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology On The Go or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In an interview with CancerNetwork®, William Kennedy, MD, a neuro-radiation oncologist at the Ivy Brain Tumor Center, provided expert insights into the current state of radiosurgery for central nervous system (CNS) tumors. Highlighting a diverse array of available radiosurgery platforms, he explained that institutions like the Ivy Brain Tumor Center frequently use noninvasive surgical techniques with complex monitoring systems.
Kennedy further underscored the critical importance of having a nuanced understanding of each technology's capabilities and limitations, as well as those of the practicing oncologist. Emphasizing a high patient volume and a wide variety of cases at his own practice, he suggested that the expertise of the staff at the Ivy Brain Tumor Center positions them at the forefront of radiosurgery development.
According to Kennedy, novel therapeutic strategies under development at Ivy Brain Tumor Center include the investigational agent AZD1390, which is being assessed in combination with radiotherapy after surgery for patients with newly diagnosed or recurrent glioblastoma.
Despite the benefits that technology provide for research advancement and treatment, Kennedy posited that the multidisciplinary team is essential in ensuring the successful delivery of novel radiosurgery techniques. This integrated approach ensures that each patient benefits from an individualized plan that leverages the full potential of modern radiosurgery.
“[D]espite all the great technologies that we have here at Ivy, what I think makes this place great, what makes me proud to work here, and what means the most for our patients is how closely we providers communicate with each other and how closely knit of a team we are,” Kennedy stated. “Being available, showing up to the tumor board, always picking up the phone when your colleague calls to discuss a tough case, and never being afraid to ask for help—all those things I have learned since I have been in practice here. Those are what make the difference, more than anything.”
Kennedy further underscored the critical importance of having a nuanced understanding of each technology's capabilities and limitations, as well as those of the practicing oncologist. Emphasizing a high patient volume and a wide variety of cases at his own practice, he suggested that the expertise of the staff at the Ivy Brain Tumor Center positions them at the forefront of radiosurgery development.
According to Kennedy, novel therapeutic strategies under development at Ivy Brain Tumor Center include the investigational agent AZD1390, which is being assessed in combination with radiotherapy after surgery for patients with newly diagnosed or recurrent glioblastoma.
Despite the benefits that technology provide for research advancement and treatment, Kennedy posited that the multidisciplinary team is essential in ensuring the successful delivery of novel radiosurgery techniques. This integrated approach ensures that each patient benefits from an individualized plan that leverages the full potential of modern radiosurgery.
“[D]espite all the great technologies that we have here at Ivy, what I think makes this place great, what makes me proud to work here, and what means the most for our patients is how closely we providers communicate with each other and how closely knit of a team we are,” Kennedy stated. “Being available, showing up to the tumor board, always picking up the phone when your colleague calls to discuss a tough case, and never being afraid to ask for help—all those things I have learned since I have been in practice here. Those are what make the difference, more than anything.”
185 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.